Literature DB >> 15711178

EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism.

Brian K Adams1, Jiyang Cai, Jeff Armstrong, Marike Herold, Yang J Lu, Aiming Sun, James P Snyder, Dennis C Liotta, Dean P Jones, Mamoru Shoji.   

Abstract

In this study, we show that the novel synthetic curcumin analog, EF24, induces cell cycle arrest and apoptosis by means of a redox-dependent mechanism in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. Cell cycle analysis demonstrated that EF24 causes a G2/M arrest in both cell lines, and that this cell cycle arrest is followed by the induction of apoptosis as evidenced by caspase-3 activation, phosphatidylserine externalization and an increased number of cells with a sub-G1 DNA fraction. In addition, we demonstrate that EF24 induces a depolarization of the mitochondrial membrane potential, suggesting that the compound may also induce apoptosis by altering mitochondrial function. EF24, like curcumin, serves as a Michael acceptor reacting with glutathione (GSH) and thioredoxin 1. Reaction of EF24 with these agents in vivo significantly reduced intracellular GSH as well as oxidized GSH in both the wild-type and Bcl-xL overexpressing HT29 human colon cancer cells. We therefore propose that the anticancer effect of a novel curcumin analog, EF24, is mediated in part by redox-mediated induction of apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711178     DOI: 10.1097/00001813-200503000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  64 in total

Review 1.  Chemopreventive potential of natural compounds in head and neck cancer.

Authors:  Mohammad Aminur Rahman; A R M Ruhul Amin; Dong M Shin
Journal:  Nutr Cancer       Date:  2010       Impact factor: 2.900

Review 2.  Lesson learned from nature for the development of novel anti-cancer agents: implication of isoflavone, curcumin, and their synthetic analogs.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Subhash Padhye
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts.

Authors:  Shijun Zhu; Terry W Moore; Xiaoqian Lin; Nao Morii; Alessandra Mancini; Randy B Howard; Deborah Culver; Richard F Arrendale; Prabhakar Reddy; Taylor J Evers; Hongzheng Zhang; Gabriel Sica; Zhuo G Chen; Aiming Sun; Haian Fu; Fadlo R Khuri; Dong M Shin; James P Snyder; Mamoru Shoji
Journal:  Integr Biol (Camb)       Date:  2012-04-25       Impact factor: 2.192

4.  Anticancer agents interacting with membrane glucose transporters.

Authors:  C Granchi; S Fortunato; F Minutolo
Journal:  Medchemcomm       Date:  2016-07-08       Impact factor: 3.597

5.  Mouse pharmacokinetics and metabolism of the curcumin analog, 4-piperidinone,3,5-bis[(2-fluorophenyl)methylene]-acetate(3E,5E) (EF-24; NSC 716993).

Authors:  Joel M Reid; Sarah A Buhrow; Judith A Gilbert; Lee Jia; Mamoru Shoji; James P Snyder; Matthew M Ames
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-24       Impact factor: 3.333

6.  Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Authors:  Karuppaiyah Selvendiran; Liyue Tong; Anna Bratasz; M Lakshmi Kuppusamy; Shabnam Ahmed; Yazhini Ravi; Nancy J Trigg; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

7.  A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells.

Authors:  Elisa Robles-Escajeda; Umashankar Das; Nora M Ortega; Karla Parra; Giulio Francia; Jonathan R Dimmock; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Cell Oncol (Dordr)       Date:  2016-02-26       Impact factor: 6.730

Review 8.  Redox-directed cancer therapeutics: molecular mechanisms and opportunities.

Authors:  Georg T Wondrak
Journal:  Antioxid Redox Signal       Date:  2009-12       Impact factor: 8.401

9.  Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.

Authors:  Andrea L Kasinski; Yuhong Du; Shala L Thomas; Jing Zhao; Shi-Yong Sun; Fadlo R Khuri; Cun-Yu Wang; Mamoru Shoji; Aiming Sun; James P Snyder; Dennis Liotta; Haian Fu
Journal:  Mol Pharmacol       Date:  2008-06-24       Impact factor: 4.436

10.  Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors.

Authors:  Igor Landais; Sanne Hiddingh; Matthew McCarroll; Chao Yang; Aiming Sun; Mitchell S Turker; James P Snyder; Maureen E Hoatlin
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.